ICU (SeaStar Medical Holding) Moat Score: 2/10 (As of Jun. 30, 2026)


ICU SeaStar Medical Holding Corp ICU
29 GF Score
Price $3.66
! 4 Warning Signs
View Full Analysis

What is SeaStar Medical Holding Moat Score?

SeaStar Medical Holding ICU +2.51% 29 Moat Score is 2 as of Jun. 30, 2026. GuruFocus rates ICU with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 1,401 Biotechnology companies, SeaStar Medical Holding ranks better than 58.1% on this metric.

SeaStar Medical Holding has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

SeaStar Medical Holding has No Moat: SeaStar Medical lacks significant market leadership and proprietary technology. The company does not possess strong brand strength or regulatory barriers, leading to minimal competitive advantages in the medical sector.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes SeaStar Medical Holding might have No Moat - Very weak/transient advantages.

SeaStar Medical Holding  (NAS:ICU) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

SeaStar Medical Holding Moat Score Related Terms

ICU vs TRAW, CALC, INAB: Moat Score Comparison

For the Biotechnology subindustry, SeaStar Medical Holding's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SeaStar Medical Holding Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's Moat Score distribution charts can be found below:

* The bar in red indicates where SeaStar Medical Holding's Moat Score falls into.


ICU
29GF Score
SeaStar Medical Holding Corp ICU
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
SeaStar Medical Holding (ICU) has a Moat Score of 2 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, SeaStar Medical Holding ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is SeaStar Medical Holding's Moat Score too high?
SeaStar Medical Holding's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. SeaStar Medical Holding's value of 2 is 0% at this industry median. Based on the distribution chart, SeaStar Medical Holding ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SeaStar Medical Holding has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's Moat Score compare to TRAW and CALC?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #587 out of 1401 companies for Moat Score. This puts SeaStar Medical Holding in the upper half of its industry. The industry median Moat Score is 2.00. SeaStar Medical Holding's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SeaStar Medical Holding's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SeaStar Medical Holding's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. SeaStar Medical Holding's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current Moat Score is 2 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SeaStar Medical Holding Business Description

Address 3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
29GF Score

Get the complete analysis for ICU

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price